CDR grafted anti-CEA antibodies and their production
AssigneeCelltech Therapeutics Limited
InventorsJohn Robert Adair, Mark William Bodmer, Andrew Mountain, Raymond John Owens
Life of this patent
Estimating the term…
Abstract
The present invention provides humanized antibody molecules (HAMs) having specificity for carcinoembryonic antigen (CEA) and having an antigen binding site wherein at least one of the complementarity determining regions (CDRs) of the variable domains is derived from the mouse monoclonal antibody A5B7 (A5B7 MAB) and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin. The HAMs may be chimeric humanized antibodies or CDR-grafted humanized antibodies and are preferably produced by recombinant DNA techniques. The HAMs are useful for in vivo diagnosis and therapy.
Claims9
An antibody molecule having specificity for carcinoembryonic antigen comprising a composite heavy chain and a complementary light chain, said composite heavy chain having a variable domain comprising the amino acid sequence of SEQ ID NO:
- 10.
An antibody molecule having specificity for carcinoembryonic antigen comprising a composite heavy chain and a complementary light chain, said composite heavy chain having a variable domain comprising the amino acid sequence of SEQ ID NO:
- 12.
An antibody molecule having specificity for carcinoembryonic antigen comprising a composite light chain and a complementary heavy chain, said composite light chain having a variable domain comprising the amino acid sequence of SEQ ID NO:
- 6.
An antibody molecule having specificity for carcinoembryonic antigen comprising a composite light chain and a complementary heavy chain, said composite light chain having a variable domain comprising the amino acid sequence of SEQ ID NO:
- 8.
An antibody molecule having specificity for carcinoembryonic antigen comprising a composite light chain and a composite heavy chain, said composite light chain having a variable domain comprising an amino acid sequence selected from SEQ ID NOs:
- 6 and 8 and said composite heavy chain having a variable domain comprising an amino acid sequence selected from SEQ ID NOs:
- 10 and 12.
Dependencies are inferred from the claim text.